glutamic-oxaloacetic transaminase 1 like 1Genealiases: []
Q-omics provides the consensus-scored GOT1L1 profile across patient tissues and cancer cell-line models. GOT1L1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, GOT1L1 is differentially expressed in 2, with the highest sampling consensus in BLCA. Additionally, GOT1L1 RNA expression shows 6,701 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and BLCA as cancer lineages where GOT1L1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GOT1L1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GOT1L1 survival associations across molecular data types. GOT1L1 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GOT1L1 RNA expression–survival associations across cancer types. High GOT1L1 expression shows unfavorable associations in STAD, LIHC, ACC, KIRC, BRCA and UVM. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify STAD as the clearest survival context for GOT1L1 RNA expression.
This table summarizes GOT1L1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for GOT1L1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GOT1L1 shows lower tumor expression in BLCA and higher tumor expression in THCA. The BLCA box plot shows higher GOT1L1 RNA expression in normal versus tumor tissue (log2 FC = −0.155, t-test p = .007).
This table shows molecular features associated with GOT1L1 in patient tissues and cancer cell lines. In patient samples, GOT1L1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, GOT1L1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
